Eli Lilly demonstrates strong bullish technical indicators including price action, momentum, and relative strength, supporting a continued uptrend. Despite receiving an 'F' valuation grade, the company's growth, profitability, and upward earnings revisions enhance its investment appeal. The recent Q1 earnings surpassed expectations with EPS of $8.55 and revenue of $19.8 billion, leading to raised guidance for 2026. Institutional investors are accumulating shares, and the stock is considered attractive unless it falls below its 30-week EMA.
The U.S. Supreme Court declined to hear Eli Lilly's appeal, leaving a $194 million whistleblower judgment intact. The case involved allegations that Eli Lilly underreported drug pricing to reduce Medicaid rebate payments by about $61 million. The rul...
Eli Lilly's Mounjaro drug revenue surged 125% to $8.66 billion last quarter, prompting a raised full-year revenue forecast of $82-$85 billion and a market cap near $882 billion. Despite this, shares have already climbed significantly, making further ...
Eli Lilly and Company announced its participation in Bernstein's 42nd Annual Strategic Decisions Conference on May 28, 2026. Daniel M. Skovronsky, the company's chief scientific and product officer, will engage in a fireside chat at 1:30 p.m. Eastern...
Novo Nordisk's oral weight-loss drug Wegovy continues to outperform Eli Lilly's Zepbound in the US market, with about 137,000 prescriptions in its 18th week, despite a 4% weekly decline. Citi notes that actual sales may be higher due to incomplete da...
Novo Nordisk is preparing to launch its Wegovy weight-loss pill outside the U.S. later this year, targeting major international markets like the UK, Germany, and Denmark. The company sees a significant opportunity to expand globally, leveraging teleh...
